Table 1.
Characteristics of patients
| Values | |
|---|---|
| HLA-A2 status, n (%) | |
| Positive | 10 (37) |
| Negative | 17 (63) |
| Number of prior therapies | 2 (1–5) |
| Age, yr, median (range) | 57 (42–69) |
| Prior therapy, n (%) | |
| Lenalidomide only | 4 (15) |
| Bortezomib only | 10 (37) |
| Both bortezomib and lenalidomide | 13 (48) |
| Race, n (%) | |
| White | 18 (67) |
| Asian | 3 (11) |
| Black or African American | 6 (22) |
| Gender, n (%) | |
| M | 16 (59) |
| F | 11 (41) |
| Cytogenetics, n (%) | |
| Normal | 15 (56) |
| Abnormal | 11 (41) |
| NA | 1 (4) |
| Myeloma subtypes, n (%) | |
| Immunoglobulin A | 4 (15) |
| Immunoglobulin G | 19 (70) |
| Light chain | 4 (15) |
| % Marrow plasmacytosis at EN | 5 (0–60) |
| β2 microglobulin level at EN, mg/L, median (range) |
1.88 (1.1–26) |
| CRP at EN, mg/dL, median (range) | 1.2 (0.2–159.6) |
| Serum-free κ, mg/L, median (range) | 11.24 (4.18–267.03) |
| Serum-free λ, mg/L, median (range) | 8.2 (1.27–1,204) |
| κ/λ ratio, median (range) | 1.46 (0.15–109.42) |
| CD4 cells/μL at EN | 552 (0–1,457) |
| CD8 cells/μL at EN | 285 (0–1,084) |
| CD3 cells/μL at EN | 828 (0–2,237) |
| M-spike at EN, g/dL, median (range) | 0.43 (0–2.60) |
NOTE: EN, enrollment; CRP, C-reactive protein; 100% of patients received either bortezomib-based or lenalidomide-based induction therapy or both.